A5090269053- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Adenosine and Purinergic Signaling
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Single-cell and spatial transcriptomics
- Cancer Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- HIV/AIDS oral health manifestations
- Gastroesophageal reflux and treatments
- Sulfur Compounds in Biology
- Immune cells in cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Corneal Surgery and Treatments
- Macrophage Migration Inhibitory Factor
- Nanoplatforms for cancer theranostics
- Lung Cancer Treatments and Mutations
- Ear and Head Tumors
Universidad Nacional de San Agustin de Arequipa
2024
The University of Texas MD Anderson Cancer Center
2017-2022
Hospital Nacional Cayetano Heredia
2015
St Martins Hospital
2014
Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in phase II study of pembrolizumab patients with advanced sarcoma (SARC028). The majority responses occurred undifferentiated pleomorphic (UPS) and dedifferentiated liposarcoma (DDLPS). sought to determine whether we can identify immune features that correlate clinical outcomes from tumor tissues obtained pre- on-treatment. Patients Methods: Pretreatment (n = 78) 8-week on-treatment 68) biopsies were stained...
Abstract Introduction CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays critical role immunosuppression and anti-tumor effects of immune checkpoint inhibitors (ICI). Here, we interrogated expression richly annotated cohort human lung adenocarcinoma (LUAD) its association with clinicopathological, immune, molecular features to better understand the this marker LUAD pathobiology. Materials methods Protein was evaluated by immunohistochemistry 106...
Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the microenvironment its association oncologic outcomes.Surgically resected samples were stained by immunohistochemistry (IHC) for following: tumor-associated cells (CD3, CD8, CD163, CD20), checkpoints (stimulatory: OX40, ICOS; inhibitory: PD-L1, LAG3, IDO1, PD1),...
The Hodgkin and Reed - Sternberg (HRS) cells in classical Lymphoma (cHL) actively modify the immune tumor microenvironment (TME) attracting immunosuppressive expressing inhibitory molecules. A high frequency of myeloid TME is correlated with an unfavorable prognosis, but more specific rare cell populations lack precise markers. Myeloid-derived suppressor (MDSCs) have been identified peripheral blood cHL patients, where they appear to be disease aggressiveness. TNFRSF9 (CD137) a T...
Introduction: Representative regions of interest (ROIs) analysis from the whole slide images (WSI) are currently being used to study immune markers by multiplex immunofluorescence (mIF) and single immunohistochemistry (IHC). However, amount area needed be analyzed representative entire tumor in a WSI has not been defined. Methods: We labeled tumor-associated cells mIF IHC separate cohorts non-small cell lung cancer (NSCLC) samples we them as well using different number ROIs know how much...
The original version of this article unfortunately contained a mistake.
El linfoma plasmablastico es una variante agresiva del difuso de celulas grandes B, descrito inicialmente en pacientes VIH positivos asociados a lesiones cavidad oral. Este corresponde al 2% LNH asociado VIH. Esta entidad actualmente representa un reto para el diagnostico y tratamiento, presentando o pobre pronostico o. presente reporte describe paciente con HIV tratamiento TARGA, recuento CD4 490 celulas/ml, Linfoma compromiso rectal medula osea. recibe regimen EPOCH por 6 ciclos respuesta completa.
<p>Supplemental Legend</p>
<p>Response to anti-PD1 therapy is associated with higher levels of PD-L1 expression by (A) tumor cells and (B) infiltrating macrophages density sarcoma-associated immune infiltrates at baseline. Tumor biopsies obtained from patients who responded pembrolizumab had baseline (cell count/mm2) (C) T lymphocytes, (D) cytotoxic (E) antigen experience (F) experienced (G) activated (H) effector memory (I) regulatory lymphocytes. Baseline samples available for profiling IHC were prior...
<p>Response to anti-PD1 therapy is associated with higher levels of PD-L1 expression by (A) tumor cells and (B) infiltrating macrophages density sarcoma-associated immune infiltrates at baseline. Tumor biopsies obtained from patients who responded pembrolizumab had baseline (cell count/mm2) (C) T lymphocytes, (D) cytotoxic (E) antigen experience (F) experienced (G) activated (H) effector memory (I) regulatory lymphocytes. Baseline samples available for profiling IHC were prior...
<div>AbstractPurpose:<p>We recently reported a 17.5% objective RECIST 1.1 response rate in phase II study of pembrolizumab patients with advanced sarcoma (SARC028). The majority responses occurred undifferentiated pleomorphic (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate clinical outcomes from tumor tissues obtained pre- on-treatment.</p>Patients Methods:<p>Pretreatment...